Skip to content
HealthyAgainDiet
← Back to Home
GLP 1 & Weight Loss

Compounded GLP-1s After June 29: What's Changing and What to Do Next

9 min read min readBy Healthy Again Diet Team

Last updated: 2026-06-29

If you've been getting compounded semaglutide or tirzepatide from a 503B outsourcing facility — the larger, FDA-registered compounding pharmacies that supply most telehealth weight-loss programs — your access is changing today. The FDA's extended comment period for 503B compounders closes, and enforcement of the prohibition on copying name-brand GLP-1s moves to the next phase.

Here's what that actually means for you, what happens with Medicare starting July 1, and the realistic paths forward for anyone who wants to stay on a GLP-1 or find a credible alternative.

What Compounded GLP-1s Were — and Why Millions Switched to Them

Ozempic (semaglutide for diabetes), Wegovy (semaglutide for weight loss), Mounjaro (tirzepatide for diabetes), and Zepbound (tirzepatide for weight loss) became household names fast. They also became impossible to get at a price most people could afford. Branded Wegovy runs $1,300–$1,700 per month without insurance. Zepbound is similar.

When both drugs landed on the FDA's drug shortage list — semaglutide in 2022, tirzepatide in 2022 as well — federal law opened a window. Compounding pharmacies, which specialize in making customized medications, were legally allowed to produce copies of drugs on the shortage list. Both 503A pharmacies (small, patient-specific operations licensed by state pharmacy boards) and 503B outsourcing facilities (larger manufacturers registered with the FDA) jumped into the market.

The result: millions of Americans accessed semaglutide or tirzepatide injections for $150–$350 per month through telehealth platforms. Companies like Hims & Hers, Ro, Henry Meds, and dozens of others built their weight-loss practices almost entirely on compounded GLP-1s.

How the FDA Shut It Down — In Stages

The FDA declared the semaglutide shortage over in February 2025 and the tirzepatide shortage over in May 2025. Under federal law, once a drug is off the shortage list, compounding pharmacies can no longer make copies — the shortage exemption disappears.

The FDA enforced this in two phases:

503A pharmacies (the smaller, patient-specific compounders) faced an earlier deadline — roughly 60–90 days after the shortage ended for each drug. By spring 2025, most 503A semaglutide compounding was already prohibited. 503A tirzepatide followed shortly after.

503B outsourcing facilities — which supplied most of the high-volume telehealth programs — were given more time, partly because they're FDA-registered and held to higher manufacturing standards, and partly because the scale of disruption was enormous. Millions of patients were receiving these medications. The FDA opened a comment period and extended the enforcement window multiple times through 2025 and into 2026.

That comment period closes today, June 29. The enforcement posture that follows is the final one.

What "Enforcement" Actually Means After June 29

The FDA doesn't raid pharmacies on the day a deadline passes. Enforcement ramps. But the legal exposure for 503B facilities shipping compounded semaglutide or tirzepatide without an active shortage exemption is now clear — and most of the large compounders have already wound down or are winding down these product lines.

What you'll likely see in the next 30–90 days:

  • Telehealth platforms that relied on 503B-compounded GLP-1s will pause or cancel subscriptions, often with short notice
  • Some platforms will pivot to prescribing brand-name drugs and helping patients pursue insurance coverage
  • 503B pharmacies that ignored the deadline will face warning letters, import alerts, and potential injunctions — not fines that they can absorb quietly
  • A secondary market of overseas pharmacies and gray-market suppliers will grow; these are unregulated and carry real safety risks

If you're currently mid-subscription and haven't heard from your provider, reach out now. Don't wait for an automated email telling you your next shipment won't arrive.

The Medicare Angle: What Changes July 1

Starting July 1, the Medicare Part D landscape for anti-obesity medications shifts again — and it matters for anyone on or considering a GLP-1.

Medicare's coverage of GLP-1s has been the most consequential insurance policy debate in weight medicine. Here's where things stand:

What Medicare has covered (and still covers): GLP-1 receptor agonists prescribed for Type 2 diabetes — Ozempic, Mounjaro, Trulicity — have been covered under Part D when the indication is diabetes management. If you have a diabetes diagnosis and your doctor prescribes semaglutide for glycemic control, Medicare covers it.

What Medicare still doesn't cover: Wegovy and Zepbound, the versions of these drugs FDA-approved specifically for obesity, have historically been excluded under Medicare rules that bar coverage of "drugs used for weight loss." The Inflation Reduction Act drug-pricing provisions that took effect in 2026 affected pricing negotiations — but the obesity-drug exclusion has been a legislative fix that Congress has debated through the Treat and Reduce Obesity Act (TROA) without final passage as of this writing.

What to watch for July 1 and beyond: If your plan year renews July 1, check your formulary. Some Medicare Advantage plans have voluntarily added coverage for anti-obesity medications ahead of any federal mandate. That coverage can change plan-to-plan and year-to-year.

If you're in Medicare and paying out of pocket for compounded GLP-1s, this regulatory moment is also a moment to revisit your coverage options. Work with a licensed Medicare insurance agent — not a telehealth platform — to understand what your specific plan covers.

Your Real Options Right Now

This is the practical part. If your compounded GLP-1 access is going away, you have four realistic paths:

Option 1: Pursue Brand-Name GLP-1s Through Insurance

The most durable solution. Yes, this requires prior authorization, documentation of BMI and weight-related comorbidities, sometimes a history of supervised diet attempts. But people who go through this process and get approved pay $0–$50/month instead of $1,300.

Start with your primary care doctor, not a telehealth platform. A PCP who knows your history can build a more persuasive case to your insurer than a telehealth prescriber who's seen you once via video.

If your insurer denies coverage, file an appeal. First-level appeals for GLP-1 denial are overturned at meaningful rates when the clinical documentation is thorough.

Option 2: Manufacturer Savings Programs

Novo Nordisk (maker of Wegovy) and Eli Lilly (maker of Zepbound) both offer savings programs for commercially insured patients. These are not charity programs — they require commercial insurance that covers the drug. But if your insurance covers it even partially, these programs can cap your out-of-pocket cost significantly.

Novo Nordisk's NovoCare program and Lilly's Savings Card programs change terms periodically, so verify current eligibility directly on their websites.

Option 3: Telehealth Platforms Pivoting to Brand-Name Access

Some telehealth companies that built on compounded GLP-1s are now pivoting to helping patients navigate brand-name access — prior auth assistance, insurer appeals, and cash-pay pricing for brand-name drugs in some cases. Sequence by Found and Noom Med are two platforms that have invested in this kind of insurance navigation support.

Affiliate Disclosure: This article may contain affiliate links. If you make a purchase through these links, we may earn a small commission at no extra cost to you. We only recommend products we genuinely believe in. This helps support our work and allows us to continue providing free content.